Feature | Coronavirus (COVID-19) | August 05, 2020| Dave Fornell, Editor

FDA Allows Emergency Use of Impella for COVID-19 Patients on ECMO

Abiomed Impella is now authorized to treat critical ICU COVID-19 patients on ECMO who develop pulmonary edema or need cardiac decompensation from myocarditis. #COVID19 #SARScov2 #Impella

Abiomed Impella is now authorized to treat critical ICU COVID-19 patients on ECMO who develop pulmonary edema or need cardiac decompensation from myocarditis.

August 5, 2020 — The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) this week for the use of Abiomed Impella left ventricular (LV) support systems to providing temporary LV unloading and support to treat critical  coronavirus (COVID‐19) patients who are already on extracorporeal membrane oxygenation (ECMO) treatment. 

The EUA specifies Impella pumps can be used if the COVID patient develops pulmonary edema while on veno-arterial (VA) ECMO support, or late cardiac decompensation from myocarditis while on veno-venous (VV) ECMO support.

This FDA authorization includes the use of the Impella 2.5, Impella CP, Impella CP with SmartAssist, Impella 5.0, and Impella 5.5 with SmartAssist percutaneous circulatory support systems for the left ventricle. 

RADM Denise M. Hinton, chief scientist, FDA, wrote in the authorization letter that COVID-19 patients may require V-A ECMO for circulatory support with oxygenation due to acute cardiopulmonary failure. However, in some patients, V-A ECMO alone does not provide sufficient LV unloading due to retrograde aortic perfusion, which can lead to LV overload and distension, resulting in pulmonary edema. The FDA said this emergency use of the Impella devices can alleviate this problem by unloading the LV, thereby reducing the LV work, and fully emptying the LV in critical care patients. 

In addition, COVID-19 patients may require V-V ECMO for pulmonary failure. Some of these patients suffer from LV decompensation from myocarditis, which may require additional mechanical circulatory support for systemic perfusion. For these patients, the Impella LV Support Systems may be effective at providing the necessary LV support for hemodynamic stability and end-organ perfusion. 

Hinton said conditions of pulmonary edema and late cardiac decompensation from myocarditis during ECMO therapy requiring temporary LV support are substantially  different than the conditions of high-risk percutaneous coronary intervention (PCI) and cardiogenic shock requiring temporary LV support, for which the Impella systems are FDA-approved to treat. However, based on the available information, including extrapolated data from the approved indications and reported clinical experience, FDA has concluded that the Impella systems may be effective at providing temporary LV support for the treatment of pulmonary edema and late cardiac decompensation in critical care ICU COVID patients.

Criteria for Issuance of Authorization for Impella in COVID Patients on ECMO

Hinton said this emergency use of the Impella pumps meets the criteria set forth by the U.S. Department of Health and Human Services (HHS) March 2020 Declaration that Circumstances Exist Justifying Authorizations due to COVID-19. These include:
   1. SARS-CoV-2, the disease that causes COVID-19, can cause a serious or life-threatening disease or condition, including severe respiratory illness, to humans infected by this virus;
   2. Based on the totality of scientific evidence available to FDA, it is reasonable to believe that the Impella LV support systems may be effective when used by healthcare professionals in the hospital setting for providing temporary LV unloading and support to treat critical care patients with confirmed COVID-19 infection who are undergoing ECMO treatment and who develop pulmonary edema while on V-A ECMO support or late cardiac decompensation from myocarditis while on V-V ECMO support, and that the known and potential benefits of the Impella systems for such use outweigh the known and
potential risks; and,
   3. There is no adequate, approved, and available alternative to the emergency use of the Impella LV support systems for critical care patients undergoing ECMO treatment for
COVID‐19 who develop pulmonary edema while on V-A ECMO support or late cardiac
decompensation from myocarditis while on V-V ECMO support.

FDA Scope of Authorized Uses for the Impella in Patients on ECMO

The scope of this authorization limits the use of the Impella pumps to four days days for Impella 2.5, Impella CP, and Impella CP with SmartAssist. It limits the use to 14 days for Impella 5.0 and Impella 5.5 with SmartAssist. 

The FDA stated Impella pumps not intended for use to treat patients with the following conditions:
   • Mural thrombus in the left ventricle;
   • Presence of a mechanical aortic valve or heart constrictive device;
   • Aortic valve stenosis/calcification (equivalent to an orifice area of 0.6 cm2 or less);
   • Moderate to severe aortic insufficiency (echocardiographic assessment graded as ≥ +2);
   • Severe peripheral arterial disease precluding placement of the Impella System;
   • Significant right heart failure; 
   • Combined cardiorespiratory failure;
   • Presence of an Atrial or Ventricular Sepal Defect (including post-infarct VSD);
   • Left ventricular rupture; or
   • Cardiac tamponade.

Read the full FDA emergency use authorization letter.

Read more about FDA emergency use authorizations for COVID-19

 

Related COVID-19 Hemodynamic Support Content:

Impella RP Granted FDA Emergency Use Authorization for COVID-19 Patients With Right Heart Failure

FDA Clears Abiomed Compact ECMO System for COVID-19 and Cardiogenic Shock Patients

FDA Approves ECMO to Treat COVID-19 Patients

LivaNova Modifies its ECMO Indications Beyond Six Hours to Address COVID-19

The Cardiovascular Impact of COVID-19

VIDEO: Multiple Cardiovascular Presentations of COVID-19 in New York — Interview with Justin Fried, M.D., explaining a case that used VV-ECMO abnd VAV-ECMO

VIDEO: Impact of COVID-19 on the Interventional Cardiology Program at Henry Ford Hospital — Interview with William O'Neill, M.D.

Kawasaki-like Inflammatory Disease Affects Children With COVID-19 

Find more cardiology related COVID-19 content

 

Reference:

 1. U.S. Department of Health and Human Services, Declaration that Circumstances Exist Justifying Authorizations Pursuant to Section 564(b) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3, 85 FR 17335 (March 27, 2020).

Related Content

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone. #SCAI21 #SCAI2021 Creating a card0-renal program.

There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal function are being excluded from interventional procedures because they are automatically considered too high risk. However, some hospitals are also creating cardio-renal care teams so these patients can be cared for by a team of experts rather than interventional cardiologists going it alone.

Feature | Cath Lab | May 14, 2021 | By Dave Fornell, Editor
There is a trend in interventional cardiology that is now being called “renalism,” where patients with poor renal fun
Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting proc

Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has gained European CE marked. This first-of-its-kind imaging software merges optical coherence tomography (OCT) intravascular imaging with the power of artificial intelligence (AI) for enhanced visualization. The new Ultreon Software can automatically detect the severity of calcium-based blockages and measure vessel diameter to enhance the precision of physicians’ decision-making during coronary stenting procedures.

News | Cath Lab | May 12, 2021
May 12, 2021 — Abbott recently announced its new interventional imaging platform powered by Ultreon 1.0 Software, has
SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI heart attack. #SCAI21 #SCAI2021

SCAI 2021 late-breaking presentations included the data on the Medtronic Harmony transcatheter pulmonary valve, cutting radial access hemostasis time by 50 percent, improving cardiogenic shock survival to 71 percent, and data showing very high mortality in COVID patients who suffer a STEMI.

Feature | Cath Lab | May 06, 2021 | By Dave Fornell, Editor
April 29, 2021 — Here is the list of late-breaking study presentations and links to articles about each of them from
Most Stable Ischemic Heart Disease Patients Did Not Meet ISCHEMIA Trial Enrollment Criteria, raising questions about its application in real-world practice. #SCAI2021 Getty Images

Getty Images

News | Cath Lab | May 03, 2021
May 3, 2021 – Results from a new study find a broad range of patients who typically undergo revascularization for sta
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab | April 29, 2021
April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 

News | Cath Lab | April 28, 2021
April 28, 2021 – Results from a retrospective observational study, presented today at...
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell

A cardiac cath lab complex PCI case at Henry Ford Hospital in Detroit. Photo by Dave Fornell

News | Cath Lab | April 28, 2021
Videos | Cath Lab | April 02, 2021
Corindus, a Siemens Healthineers company and a developer of vascular robotics, recently launched a new set of automat
Videos | Cath Lab | March 31, 2021
This is a quick example of clinical use of the Shockwave Medical Intravascular Lithotripsy system that uses sonic wav